Safety and antihypertensive effect of switching from eplerenone to esaxerenone in hypertensive patients.

Safety and antihypertensive effect of switching from eplerenone to esaxerenone in hypertensive patients. - Safety and antihypertensive effect of switching from eplerenone to esaxerenone in hypertensive patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037722

Enrollment

200

Registered

2019-08-19

Start date

2024-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive patients

Interventions

esaxerenone 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have been administered eplerenone for more than 8 weeks.

Exclusion criteria

Exclusion criteria: Patients with heart failure. Patients who have taken potassium-sparing diuretics (spironolactone, triamterene, and potassium canrenoate) or potassium preparations during the last 8 weeks. Patients whose serum potassium level exceeded 5.0 mEq/L. Patients with severe renal dysfunction (eGFR <30 mL/min/1.73m2).

Design outcomes

Primary

Measure	Time frame
Changes in blood pressure, pulse rate, serum levels of potassium and creatinine, and eGFR.	—

Countries

Japan

Contacts

Public ContactNobukazu Sasaki

Tokyo Women's Medical University Department of Endocrinology and Hypertension

sasaki.nobukazu@twmu.ac.jp+81-333538111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026